On the heels of a new Food and Drug Administration approval for its billion-dollar drug Xgeva, Amgen announced that the European Medicines Agency would consider an application for osteoporosis drug Evinity. Evinity, developed in conjunction with Brussels-based UCB, aims to treat osteoporosis and reduce the risk of fracture in higher-risk populations, including postmenopausal women, by…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
